Experienced in Dacryoadenitis

Dr. Joseph Tauber

Ophthalmology
4400 Broadway St, Ste 202, 
Kansas City, MO 
Accepting New Patients
Experienced in Dacryoadenitis
4400 Broadway St, Ste 202, 
Kansas City, MO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Joseph Tauber is an Ophthalmologist in Kansas City, Missouri. Dr. Tauber is rated as an Experienced provider by MediFind in the treatment of Dacryoadenitis. His top areas of expertise are Dry Eye Syndrome, Meibomianitis, Episcleritis, and Scleritis. Dr. Tauber is currently accepting new patients.

His clinical research consists of co-authoring 31 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Dacryoadenitis.

Specialties
Ophthalmology
Licenses
Ophthalmology in KS
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

4400 Broadway St, Ste 202, Kansas City, MO 64111

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Multicenter, Randomized, Double-Masked, Dose-Ranging Study To Compare The Ocular Safety, Tolerability, And Efficacy Of SURF-200 Ophthalmic Solution (0.02% And 0.04% Betamethasone Sodium Phosphate) To Vehicle In Subjects With A Diagnosis Of Dry Eye Disease And Experiencing An Episodic Flare Up
A Multicenter, Randomized, Double-Masked, Dose-Ranging Study To Compare The Ocular Safety, Tolerability, And Efficacy Of SURF-200 Ophthalmic Solution (0.02% And 0.04% Betamethasone Sodium Phosphate) To Vehicle In Subjects With A Diagnosis Of Dry Eye Disease And Experiencing An Episodic Flare Up
Enrollment Status: Completed
Publish Date: June 04, 2025
Intervention Type: Drug
Study Drug: Betamethasone Sodium Phosphate
Study Phase: Phase 2
A Multicenter, Randomized, Double-Masked Study To Evaluate The Safety, Tolerability, And Efficacy Of SURF-100 Ophthalmic Solution (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination) In Subjects With Dry Eye Disease
A Multicenter, Randomized, Double-Masked Study To Evaluate The Safety, Tolerability, And Efficacy Of SURF-100 Ophthalmic Solution (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination) In Subjects With Dry Eye Disease
Enrollment Status: Completed
Publish Date: May 11, 2025
Intervention Type: Drug
Study Drugs: Combination of Mycophenolic Acid and Betamethasone Sodium Phosphate, Mycophenolic Acid, Restasis Ophthalmic Emulsion, Xiidra Ophthalmic Solution
Study Phase: Phase 2
A 4 Weeks, Phase II, Multicenter, Randomized, Double-masked, Vehicle-controlled, Parallel Group Study With 12 Weeks of Follow-up to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution vs Vehicle in Moderate to Severe Dry Eye.
A 4 Weeks, Phase II, Multicenter, Randomized, Double-masked, Vehicle-controlled, Parallel Group Study With 12 Weeks of Follow-up to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution vs Vehicle in Moderate to Severe Dry Eye.
Enrollment Status: Completed
Publish Date: April 19, 2024
Intervention Type: Drug, Other
Study Phase: Phase 2
A Phase I/II Prospective, Randomized, Multicenter, Double-Masked, Vehicle-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Corneal Collagen Cross-Linking of Keratoprosthesis Carrier Tissue in High-Risk Keratoprosthesis Implantation
A Phase I/II Prospective, Randomized, Multicenter, Double-Masked, Vehicle-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Corneal Collagen Cross-Linking of Keratoprosthesis Carrier Tissue in High-Risk Keratoprosthesis Implantation
Enrollment Status: Completed
Publish Date: May 10, 2023
Intervention Type: Drug, Device
Study Phase: Phase 1/Phase 2
A Phase 3, Multicenter, Randomized, Double-masked, and Placebo-controlled Study Evaluating the Efficacy and Safety of a 5.0% Concentration of Lifitegrast Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease and History of Recent Artificial Tear Use
A Phase 3, Multicenter, Randomized, Double-masked, and Placebo-controlled Study Evaluating the Efficacy and Safety of a 5.0% Concentration of Lifitegrast Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease and History of Recent Artificial Tear Use
Enrollment Status: Completed
Publish Date: June 11, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase III, Double-Masked, Randomized, Controlled Trial of KPI-121 in Postsurgical Inflammation
A Phase III, Double-Masked, Randomized, Controlled Trial of KPI-121 in Postsurgical Inflammation
Enrollment Status: Completed
Publish Date: January 29, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Enrollment Status: Completed
Publish Date: January 05, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 1b, Open-Label, Multiple Dose, Proof-of-Concept Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis
A Phase 1b, Open-Label, Multiple Dose, Proof-of-Concept Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis
Enrollment Status: Completed
Publish Date: August 29, 2019
Intervention Type: Drug
Study Phase: Phase 1
Randomized, Double-Masked, Parallel Group Study of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease Assessing Safety and Efficacy Over 28 Days
Randomized, Double-Masked, Parallel Group Study of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease Assessing Safety and Efficacy Over 28 Days
Enrollment Status: Terminated
Publish Date: October 11, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 8 Less Clinical Trials

30 Total Publications

TFOS DEWS III Management and Therapy Report.
TFOS DEWS III Management and Therapy Report.
Journal: American journal of ophthalmology
Published: May 23, 2025
Similar Doctors
Advanced in Dacryoadenitis
Dr. Matthew C. Sniegowski
Ophthalmology
Advanced in Dacryoadenitis
Dr. Matthew C. Sniegowski
Ophthalmology

University Health Physicians

2101 Charlotte St, 
Kansas City, MO 
 (2.9 miles away)
816-404-2222
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Matthew Sniegowski is an Ophthalmologist in Kansas City, Missouri. Dr. Sniegowski is rated as a Distinguished provider by MediFind in the treatment of Dacryoadenitis. His top areas of expertise are Entropion, Conjunctivitis (Pink Eye), Blocked Tear Duct, and Eyelid Bump. Dr. Sniegowski is currently accepting new patients.

Advanced in Dacryoadenitis
Dr. Jason Sokol
Ophthalmology | Pediatrics
Advanced in Dacryoadenitis
Dr. Jason Sokol
Ophthalmology | Pediatrics

Kansas University Physicians Inc

4000 Cambridge St, 
Kansas City, KS 
 (1.1 miles away)
913-588-1227
Languages Spoken:
English
See accepted insurances

Jason Sokol is an Ophthalmologist and a Pediatrics provider in Kansas City, Kansas. Dr. Sokol is rated as a Distinguished provider by MediFind in the treatment of Dacryoadenitis. His top areas of expertise are Graves Disease, Anophthalmia Plus Syndrome, Blocked Tear Duct, Nerve Decompression, and Tissue Biopsy.

Experienced in Dacryoadenitis
Dr. David B. Lyon
Ophthalmology
Experienced in Dacryoadenitis
Dr. David B. Lyon
Ophthalmology
11261 Nall Ave, 
Leawood, KS 
 (9.0 miles away)
913-261-2020
Languages Spoken:
English
See accepted insurances
Accepting New Patients

David Lyon is an Ophthalmologist in Leawood, Kansas. Dr. Lyon is rated as a Distinguished provider by MediFind in the treatment of Dacryoadenitis. His top areas of expertise are Benign Essential Blepharospasm, Strabismus, Chalazion, and Esotropia. Dr. Lyon is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tauber's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 10 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile